Sungen: Bispecific Antibody, Bispecific Antibody Companies

Sungen Biomedical was founded in 2019 which is an innovative antibody drug research and development enterprise incubated by Hotgen Biotech (SH688068), a listed company on the Shanghai Stock Exchange. The co-founder of Sungen Biomedical is Professor Zhiwei Sun, Vice Chairman of China Monoclonal Antibody Industry Committee.

Learn More About Us 

What Does Sungen Achieve?

Sungen Biomedical, founded in 2019 and incubated by Hotgen Biotech, specializes in innovative antibody drugs and large molecule biopharmaceuticals. With a robust R&D pipelines, cutting-edge technology platforms, and strategic collaborations, we are committed to advancing medical science and improving patient outcomes globally.

Explore Sungen Research Innovation 

Technological Platforms

Innovation Achievements

Scientific Frontiers

Sungen News

View all articles 

May

Opportunities and Challenges of AI-Powered Drug Development

Artificial intelligence (AI) is revolutionizing pharmaceutical research and development (R&D), offering transformative opportunities to address the industry’s challenges of high costs, long timel...

Read article >

May

Sungen Biomedical obtained the honorary title of Model Collective of Beijing Municipality

On April 29th, the Commendation Conference for Model Workers, Advanced Workers and Model collectives in Beijing was grandly held at Beijing Conference Center. Approved by the Beijing Municipal Committ...

Read article >

May

Sungen Biomedical is listed on the 3rd KPMG China's Top 50 Bioinnovation Companies

On April 28, KPMG China officially released "The 3rd KPMG China's Top 50 Bioinnovation Companies" list. Beijing Sungen Biomedical Technology Co., Ltd. (referred to as "Sungen Biomed...

Read article >